An observational study in Progressive Supranuclear Palsy and Corticobasal Degeneration, sponsored by University of California, San Francisco. Completed at 2 sites in United States. Open to participants aged 45 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-05-08.
Sponsored by University of California, San Francisco · Observational
The purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in the hope that this information can be used to guide diagnosis and treatment of PSP and CBD in the future. Recent advances in our understanding of the biological causes of these diseases offer hope for new treatments. As such treatments are developed, sensitive and specific biological measurements (biomarkers) will be needed to provide precise and direct measures of the state of the brain, which will improve the statistical power of clinical trials. Brain imaging with Magnetic Resonance Imaging (MRI) has previously been used to measure disease-related changes in the brain. The goal of this study is to identify the best methods of analysis (including eye movements, imaging, and behavioral measures) for tracking PSP and CBD over time. In addition, certain biomarkers in the blood and cerebrospinal fluid might also be useful for following these diseases over time. This study will examine the value of blood and CSF biomarkers relative to brain imaging and functional measures.
162 studies on the registry are indexed under Supranuclear Palsy, Progressive; 48 are open to participants now.
This study's planned enrollment of 110 is below the median of 200 across 63 observational studies indexed under Supranuclear Palsy, Progressive.
Browse Supranuclear Palsy, Progressive studies →University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.
Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects with a diagnosis of PSP or CBD
Exclusion Criteria:
Other: Observational Study
Progressive Supranuclear Palsy Rating Scale
Change from baseline
Time frame: Baseline, 6 months and 1 year
Eye movement function
Change from baseline
Time frame: Baseline, 6 months and 1 year
Brain volume on MRI
Change from baseline.
Time frame: Baseline, 6 months and 1 year
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supranuclear Palsy, Progressive→
University of California, San Francisco